Marty Makary, the 27th Commissioner of the U.S. FDA, shared a post on X:
“Two Days after receiving the application, FDA greenlit the new pancreatic cancer drug daraxonrasib for expanded access.
This drug has also been granted a national priority voucher, which means a full application could be reviewed in a matter of weeks instead of 10-12 months.”
Other articles about Pancreatic Cancer on OncoDaily.